(redirected from ADCC)
Also found in: Thesaurus, Medical, Acronyms, Wikipedia.


Of, relating to, or producing a toxic effect on cells.

cy′to·tox·ic′i·ty (-tŏk-sĭs′ĭ-tē) n.


(ˌsaɪ toʊ tɒkˈsɪs ɪ ti)

cell destruction caused by a cytotoxin.
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.cytotoxicity - the degree to which something is toxic to living cells
toxicity - the degree to which something is poisonous


n. citotoxicidad, la capacidad de un agente de destruir ciertas células.
Mentioned in ?
References in periodicals archive ?
ADCC activity is a key antibody function that results in selective destruction of target cells, including cancerous cells or pathogen-infected cells.
To overcome the variability resulting from both cell donor sources and Fc receptors, laboratories have developed modified cell lines that either enhance the NK ADCC response by down regulating NK cell inhibitory signals (J Immunol.
Can the relative contributions of ADCC and target inhibition toward tumor shrinkage be quantified?
The super fight was announced in 2009 when Braulio won his weight class and the open-weight class at the previous ADCC to set up the contest against the strikeforce star.
Professor Stephen Kent of the University of Melbourne and one of the senior authors on the paper said ADCC antibodies have been strongly implicated in protection from HIV in several vaccine trials but their action was poorly understood.
The group at the University of Melbourne's Department of Microbiology and Immunology analyzed blood samples of people with HIV and found their virus had evolved to evade or 'escape' the ADCC antibodies against HIV they are making to try to control their virus.
Research shows that POTELLIGENT(R) Technology dramatically enhances ADCC activity of an antibody in vitro, and significantly increases potency and efficacy of the antibody in vivo.
But ADCC Lawson said the aim was to improve safety on Merseyside's roads.
Preclinice I in-vitro studies showed that this second-generation nonfucosylated anti-CD30 antibody demonstrated enhanced ADCC (antibody-dependent cellular cytotoxicity), an important mechanism of action of therapeutic antibodies, and was active in inhibiting tumour growth in in-vivo xenograft models.
Targeting cancer-specific membrane protein owned by OncoTherapy, the two companies will create an antibody with improved ADCC (antibody-dependent cellular cytotoxicity) activity using BioWa's proprietary antibody technology POTELLIGENT.
An essential pre-condition for commenting on the origins of Anzac Day observance would be a detailed consultation of the records of the ADCC in the Oxley Library in Brisbane supplemented by the files of the Prime Minister's Department relating to Anzac Day.